Subsets of No-T2D and T2D patients (Table 1) were randomly selected and further divided according to their RYGB postoperative diabetes remission status for the measurements of the FGF19/21 serum levels (Tables A and B in S1 File). This evidence concerns the gene FGF19 and diabetes mellitus.